NeoCor Therapeutics develops small‑molecule and biologic candidates that block cardiomyocyte death, stimulate endogenous cardiac regeneration, and limit fibrotic scarring to preserve heart function.
Funding
Funding not disclosed
Founders
Product
Problem
Heart disease often progresses to heart failure because existing treatments do not stop cardiomyocyte loss, insufficiently promote regeneration, and fail to prevent fibrotic scarring, leading to declining cardiac function and reduced patient lifespan.
Solution
NeoCor develops therapeutic candidates that intervene in the fundamental pathways of cardiac injury. By blocking signals that trigger cardiomyocyte death, the platform preserves existing heart muscle cells. It simultaneously activates regenerative programs to generate new, functional cardiomyocytes, and incorporates anti‑fibrotic mechanisms to limit non‑contractile scar tissue formation. These combined actions aim to maintain cardiac contractility, halt disease progression, and ultimately improve survival and quality of life for patients with chronic cardiac conditions.
Target Audience
Primary customers are pharmaceutical companies and biotech firms seeking to license or co‑develop advanced cardiac therapeutics, as well as clinical research organizations conducting late‑stage heart failure trials.
Features
- Small‑molecule and biologic candidates designed to inhibit apoptosis pathways in cardiomyocytes
- Regenerative agents that stimulate endogenous cardiac progenitor cells to differentiate into functional cardiomyocytes
- Anti‑fibrotic compounds that reduce extracellular matrix deposition and preserve myocardial elasticity
- Integrated preclinical validation pipeline using human‑relevant cardiac models to assess efficacy and safety
- Platform approach targeting multiple disease mechanisms to provide synergistic cardiac protection